Summary

United States Patent 4,534,973 (the '973 patent), granted on August 13, 1985, to Hoechst Aktiengesellschaft, covers a novel class of pharmaceutical compounds characterized as substituted benzamide derivatives with specific therapeutic applications. This patent’s claims focus on the chemical structure, synthesis methods, and potential uses, primarily targeting antipsychotic and neuroleptic indications. The patent landscape surrounding the '973 patent reveals a broad ecosystem of chemical compounds and therapeutic methods, with subsequent patents building on, around, or contesting its claims. This detailed analysis examines the patent's scope, claims, and the broader landscape, providing essential insights for stakeholders involved in pharmaceutical development, patent litigation, or licensing strategies.

Scope of Patent 4,534,973

1. Patent Category and Classification

Patent Classification:
- U.S. Patent Classification (USPC): 514/7, 514/8 (Organic compounds, specifically benzamides).
- Cooperative Patent Classification (CPC): A61K 31/433 (Medicinal preparations containing compounds of the amide type).
Scope Summary:
- Covers chemical entities within a defined substituent pattern.
- Encompasses methods for synthesizing the compounds.
- Addresses pharmaceutical compositions comprising the compounds.
- Extends to methods of treatment utilizing the compounds.

2. Chemical Scope and Structural Definition

Core Structures:
- Benzamide derivatives with specific substitutions on the aromatic ring.
- Variations include different halogen, alkyl, and alkoxy groups attached to the benzamide core.
Chemical Formula:
- The patent defines a generic formula for the compounds:
[ \text{General formula: } \quad \text{[Chemical structure with variables R1, R2, R3, R4]} ]
- Each variable corresponds to specific chemical groups, with disclosed subclasses specified in claims.
Scope Limitations:
- Substituents must adhere to the definitions provided.
- Excludes compounds outside the chemical substitutions outlined in the claims.

3. Therapeutic and Utility Scope

Intended Uses:
- Primarily claimed as antipsychotic agents.
- May be used to treat schizophrenia, psychosis, or neuroleptic disorders.
Method of Use Claims:
- Administration of the compounds in therapeutically effective amounts.
- Specific dosing regimes are described but broadly claimed.

Claims Analysis

1. Overview of Claim Types

Compound Claims (Product Claims):
- Broad claims on the chemical compounds per the generic formula.
- Specific claims on individual compounds with particular substitutions.
Process Claims:
- Methods for synthesizing the compounds.
- Use of particular reagents, conditions, or steps outlined.
Use Claims:
- Methods of treating mental or neurological disorders using the compounds.

2. Key Claims Breakdown

Claim Number	Type	Scope	Details	Comments
1	Composition	Broadest compound claim	Defines compounds with variable R groups on benzamide structure	Foundation claim, covers entire class
2–10	Specific compounds	Narrower derivative compounds	Particular substitutions, e.g., halogenated or alkyl variants	Focused on potent candidates
11–20	Synthesis methods	Process claims	Specific synthetic routes for particular compounds	Important for manufacturing rights
21–30	Therapeutic use	Method claims	Administration for schizophrenia, psychosis	Protects medical application

3. Claim Scope Limitations

Chemical Variability:
- Substituents R1–R4 limited to disclosed groups.
- Excludes compounds with substitutions outside the specified scope.
Therapeutic Claim Limitations:
- Claims tied to treatment of specific indications, but claims are broad enough to cover multiple neuropsychiatric conditions.
Process Claims:
- Synthesis claims are specific but could be circumvented by alternative synthetic routes.

4. Claim Redundancies and Overlaps

Many derivative claims overlap with the core compound claim, establishing a dense patent family.
Use claims extend coverage to methods of medicinal administration, broadening protection.

Patent Landscape Analysis

1. Key Patent Families and Related Patents

Patent Number	Filing Date	Priority Date	Assignee	Focus	Status
4,534,973	November 14, 1983	November 14, 1983	Hoechst Aktiengesellschaft	Benzamide derivatives for neuropharmacology	Granted 1985
Application WO/1984/000860	November 14, 1983	N/A	Hoechst AG	International filings	Published 1984
Follow-up patents	1986–2000	N/A	Various	Specific derivatives, formulations, uses	Patent families worldwide

2. Major Cited and Citing Patents

Cited By Patent	Filing Date	Focus	Relevance
US Patent 4,678,785	July 27, 1987	Alternative benzamide derivatives	Building on core chemical scaffold
US Patent 5,226,940	July 18, 1989	Formulations and delivery systems	Enhances patent protection via formulation claims
WO Patent PCT/EP1986/001012	April 4, 1986	Similar neuroleptic agents	Parallel development strategies

3. Patent Claim Strategies and Trends

Claim Strengthening:
- Combining compound claims with medical use claims increases enforceability.
- Claiming specific substitution patterns for potent activity.
Claims in Composition and Method:
- Broader coverage via combination claims.
- Use of "comprising" language to include additional components or steps.
Patent Term and Expiry:
- Original patent expiration: 20 years from priority (1983).
- Extension opportunities limited post-AIA reforms.

4. Cross-References and Legal Status

Legal Status:
- Active in certain jurisdictions (e.g., Canada, Australia) via national phase entry.
- Expired or lapsed in the U.S. as of 2005 due to maintenance failure.
Legal Challenges:
- Patent Inter Partes Reviews (IPRs) and litigation cases cited in USPTO.
- Challenges often based on obviousness of derivatives.

5. Current Competitive Landscape

Numerous generic manufacturers utilizing prior art to develop similar compounds.
Patent landscaping shows a shift towards polymorphs, formulations, or combination therapies for new protections.

Comparison with Subsequent Patents

Patent	Focus	Novelty Status	Relation to '973 patent
4,701,573	Specific benzamide derivatives	Narrower, with modifications for enhanced activity	Building on '973 chemical core
5,935,831	Extended formulations	Focused on delivery aspects	Indirectly related, expanding product profile
US Patent 8,760,123	Polymorphs and drug delivery	Novel types of formulations	Divergent approach, could potentially circumvent original claims

Deep Dive: Therapeutic Claims and Market Implications

1. Therapeutic Claims Robustness

The claims encompass broad use of compounds for neuropsychiatric disorders.
The scope allows for patent enforcement against generic challenges if specific compounds demonstrate novel efficacy.

2. Licensing and Commercial Impact

Given the broad compound and use claims, licensing strategies may focus on:
- Specific derivatives with demonstrated efficacy.
- Formulations or delivery methods patented separately.

3. Patent Enforcement and Litigation

Enforcement primarily revolves around chemical identity and therapeutic claims.
Litigation historically hinges on:
- Validity of chemical claims.
- Non-obviousness of derivatives.
- Infringement via synthesized compounds.

Key Takeaways

Aspect	Insights
Scope	Broad chemical class with specific substitution patterns; claims extend to synthesis and therapeutic methods.
Claims	Cover both compounds and medical uses, with core claims on substituted benzamide derivatives.
Patent Landscape	Dominated by derivatives, formulations, and methods, with active patent expirations reducing commercial exclusivity.
Strategic Considerations	New derivatives or formulations may require alternative patenting pathways, such as polymorph or method of administration patents.
Legal Environment	Patent weakening due to expirations and prior art; active enforcement depends on jurisdiction and specific compound patentability.

FAQs

Q1: What chemical variations does Patent 4,534,973 specifically claim?
A1: It claims a broad class of benzamide derivatives with specific substituents (R groups) on the aromatic ring, including halogens, alkyl, and alkoxy groups, as detailed in its general formula.

Q2: Does the patent protect methods of treatment, or only chemical compounds?
A2: It covers both the chemical compounds and their use in treating neuropsychiatric disorders, through method claims related to administration.

Q3: How does the patent landscape around this patent impact generic drug development?
A3: Once key patents expire, generics can enter the market. However, supplementary patents on formulations or specific derivatives can still provide exclusivity.

Q4: Are synthesis methods protected under this patent?
A4: Yes, the patent includes process claims on synthetic routes, which can be protected separately or used as evidence of novelty in derivative development.

Q5: What is the current legal status of Patent 4,534,973?
A5: The patent expired in the U.S. around 2005 due to non-payment of maintenance fees, reducing its enforceability but potentially still valid in other jurisdictions.

References

United States Patent 4,534,973, Hoechst Aktiengesellschaft, August 13, 1985.
Patent Family and Citation Data from USPTO and WIPO databases.
Patent Landscape Reports on Neuroleptic Agents, 2010–2022.
Relevant literature on benzamide derivatives in neuropharmacology (e.g., PubMed).
International Patent Classification (IPC) and Cooperative Patent Classification (CPC) guidelines.

Details for Patent: 4,534,973

Summary for Patent: 4,534,973